Kazumi Mori-Anai

8PUBLICATIONS
13CO-AUTHORS
PharmacogenomicsMolecular medicineMolecular targetsBiomolecular modelling and design
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Feb 29, 2024
Publisher Correction: Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model.

Hiroaki Iijima, Hidetoshi Shimizu, Kazumi Mori-Anai

|Feb 27, 2024
Renal outcomes with sodium-glucose cotransporter 2 inhibitors in Japanese people with grade 3 chronic kidney disease and type 2 diabetes: Analysis of medical administrative databases.

Hiroaki Iijima, Maki Gouda, Hideaki Hida

|Dec 20, 2023
Evaluation of Age-Related Changes in Teneligliptin Pharmacokinetics in Japanese and European Descent Subjects Using a Physiologically Based Pharmacokinetic Model.

Hiroaki Iijima, Hidetoshi Shimizu, Kazumi Mori-Anai

|Jul 21, 2022
Effect of canagliflozin on the decline of estimated glomerular filtration rate in chronic kidney disease patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase III study in Japan.

Takashi Wada, Kazumi Mori-Anai, Akiko Takahashi

|Feb 09, 2022
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.

Takashi Kadowaki, Nobuya Inagaki, Hirotaka Watada

|Dec 02, 2021
Real-World Safety and Effectiveness of Canagliflozin Treatment for Type 2 Diabetes Mellitus in Japan: SAPPHIRE, a Long-Term, Large-Scale Post-Marketing Surveillance.

Nobuya Inagaki, Masaomi Nangaku, Yasushi Sakata

Pageof 2

Frequent Collaborators

3 joint publications

Hiroaki Iijima

2 joint publications

Kazuyo Sasaki

2 joint publications

Hidetoshi Shimizu

2 joint publications

Toshimasa Yamauchi